丙型肝炎病毒感染后大多數(shù)患者轉(zhuǎn)為慢性感染,若不及時正確地進(jìn)行治療,相當(dāng)比例患者會產(chǎn)生嚴(yán)重臨床后果,丙型肝炎患者一旦確診應(yīng)積極行抗病毒治療。根據(jù)病毒基因型及患者治療過程中病毒學(xué)應(yīng)答情況來預(yù)測療效并相應(yīng)調(diào)整治療方案,成為目前抗病毒治療的研究熱點。
引用本文: 郭麗琳,雷學(xué)忠. 慢性丙型肝炎抗病毒治療個體化療程選擇. 華西醫(yī)學(xué), 2012, 27(9): 1431-1433. doi: 復(fù)制
1. | Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation[J]. Liver Transpl, 2009, 15(9): 1063-1071. |
2. | 慢性丙型肝炎抗病毒治療專家委員會. 慢性丙型肝炎抗病毒治療專家共識[J]. 中華實驗和臨床感染病雜志·電子版, 2009, 3(3): 343-352. |
3. | Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment[J]. Gastroenterology, 2006, 131(2): 451-460. |
4. | Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1352-1374. |
5. | Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1b infected chronic hepatitis C patients:a randomised trial[J]. Hepatology, 2008, 47(6): 1884-1893. |
6. | Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269. |
7. | Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients[J]. Hepatology, 2009, 50(2): 369-377. |
8. | Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis[J]. J Hepatol, 2010, 52(1): 25-31. |
9. | Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin[J]. Gastroenterology, 2006, 130(4): 1086-1097. |
10. | Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders[J]. Hepatology, 2007, 46(6): 1688-1694. |
11. | Farnik H, Lange CM, Sarrazin C, et al. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection[J]. Clin Gastroenterol Hepatol, 2010, 8(10): 884-890. |
12. | 成軍. 慢性丙型肝炎治療的新進(jìn)展[J]. 中華實驗和臨床感染病雜志: 電子版, 2010, 4(1): 1-5. |
13. | Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C[J]. Am J Gastroenterol, 2009, 104(1): 70-75. |
14. | Chayama K, Hayes CN, Yoshioka K, et al. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C[J]. J Gastroenterol, 2011, 46(4): 545-555. |
15. | Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial[J]. Hepatology, 2008, 47(1): 43-50. |
16. | European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection[J]. Hepatology, 2011 ,55(2): 245-264. |
17. | Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[J]. N Engl J Med, 2007, 357(2): 124-134. |
18. | Dalgard O, Bjøro K, Ring-Larsen H, et al. A randomized controlled trial of pegylated interferon alfa and ribavirin for 14 vs 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response[J]. Hepatology, 2008, 47(1): 35-42. |
19. | Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C[J]. Gut, 2007, 56(4): 553-559. |
20. | Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C[J]. J Hepatol, 2008, 49(4): 634-651. |
21. | Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C[J]. J Hepatol, 2008, 48(5): 721-727. |
22. | Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection[J]. Hepatology, 2009, 49(2): 358-363. |
23. | Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha 2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection[J]. Hepatology, 2008, 47(6): 1837-1845. |
24. | Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3without a rapid virologic response[J]. Hepatol, 2007, 46(Suppl 1): S6. |
25. | Shiffman ML, Minola E, Barange K, et al. Characterisation of HCV genotype 2/3 patients without a rapid virological response (RVR) optimising treatment by predicting slower responders to peginterferon a2a plus ribavirin[J]. Hepatol, 2007, 46(Suppl 1): S245. |
26. | Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6[J]. Hepatology, 2010, 52(5): 1573-1580. |
27. | Zhou YQ, Wang XH, Hong GH, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a[J]. J Viral Hepat, 2011, 18(8): 595-600. |
- 1. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation[J]. Liver Transpl, 2009, 15(9): 1063-1071.
- 2. 慢性丙型肝炎抗病毒治療專家委員會. 慢性丙型肝炎抗病毒治療專家共識[J]. 中華實驗和臨床感染病雜志·電子版, 2009, 3(3): 343-352.
- 3. Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment[J]. Gastroenterology, 2006, 131(2): 451-460.
- 4. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1352-1374.
- 5. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1b infected chronic hepatitis C patients:a randomised trial[J]. Hepatology, 2008, 47(6): 1884-1893.
- 6. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269.
- 7. Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients[J]. Hepatology, 2009, 50(2): 369-377.
- 8. Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis[J]. J Hepatol, 2010, 52(1): 25-31.
- 9. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin[J]. Gastroenterology, 2006, 130(4): 1086-1097.
- 10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders[J]. Hepatology, 2007, 46(6): 1688-1694.
- 11. Farnik H, Lange CM, Sarrazin C, et al. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection[J]. Clin Gastroenterol Hepatol, 2010, 8(10): 884-890.
- 12. 成軍. 慢性丙型肝炎治療的新進(jìn)展[J]. 中華實驗和臨床感染病雜志: 電子版, 2010, 4(1): 1-5.
- 13. Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C[J]. Am J Gastroenterol, 2009, 104(1): 70-75.
- 14. Chayama K, Hayes CN, Yoshioka K, et al. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C[J]. J Gastroenterol, 2011, 46(4): 545-555.
- 15. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial[J]. Hepatology, 2008, 47(1): 43-50.
- 16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection[J]. Hepatology, 2011 ,55(2): 245-264.
- 17. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[J]. N Engl J Med, 2007, 357(2): 124-134.
- 18. Dalgard O, Bjøro K, Ring-Larsen H, et al. A randomized controlled trial of pegylated interferon alfa and ribavirin for 14 vs 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response[J]. Hepatology, 2008, 47(1): 35-42.
- 19. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C[J]. Gut, 2007, 56(4): 553-559.
- 20. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C[J]. J Hepatol, 2008, 49(4): 634-651.
- 21. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C[J]. J Hepatol, 2008, 48(5): 721-727.
- 22. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection[J]. Hepatology, 2009, 49(2): 358-363.
- 23. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha 2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection[J]. Hepatology, 2008, 47(6): 1837-1845.
- 24. Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3without a rapid virologic response[J]. Hepatol, 2007, 46(Suppl 1): S6.
- 25. Shiffman ML, Minola E, Barange K, et al. Characterisation of HCV genotype 2/3 patients without a rapid virological response (RVR) optimising treatment by predicting slower responders to peginterferon a2a plus ribavirin[J]. Hepatol, 2007, 46(Suppl 1): S245.
- 26. Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6[J]. Hepatology, 2010, 52(5): 1573-1580.
- 27. Zhou YQ, Wang XH, Hong GH, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a[J]. J Viral Hepat, 2011, 18(8): 595-600.